Medical importance of Staphylococcus epidermidis biofilm in joint prosthesis infections

Authors

  • Silvestre Ortega-Peña Laboratorio de Infectología, Instituto Nacional de Rehabilitación.
  • Rafael Franco-Cendejas Laboratorio de Infectología, Instituto Nacional de Rehabilitación.

Keywords:

Cerebral palsy, drooling, botulinum toxin type A

Abstract

Joint replacement is a surgical procedure performed in patients with articular wear. This surgery
helps them to improve their mobility and quality of life; however, it can cause complications in
some cases. Prosthetic joint infection is the most serious and catastrophic complication that may
occur after a joint replacement procedure. The most common etiologic agent in these infections
is Staphylococcus epidermidis. Prosthetic joint infections that are caused by S. epidermidis are
usually chronic and persistent because these microorganisms are found as a biofilm. This biofilm
is a barrier that protects the bacterial cells from the action of antibiotics and the host’s immune
response. The formation of the biofilm is a complex process that occurs in four phases. Better
understanding of the pathophysiology of infections caused by biofilm-producing microorganisms
can help to find more effective therapeutic strategies.

Publication Facts

Metric
This article
Other articles
Peer reviewers 
0
2.4

Reviewer profiles  N/A

Author statements

Author statements
This article
Other articles
Data availability 
N/A
16%
External funding 
N/A
32%
Competing interests 
No
11%
Metric
This journal
Other journals
Articles accepted 
18%
33%
Days to publication 
25
145

Indexed in

Editor & editorial board
profiles
Academic society 
N/A

References

Lim M, Mace A, Reza N, Sandhu G. Botulinum toxin in

the management of sialorrhoea: a systematic review.

Clin Otolaryngol. 2006; 31: 267-272.

Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N,

Dan B et al. Executive Committee for the Defi nition of Cere-

bral palsy. Proposed defi nition and classifi cation of cerebral

palsy. Dev Med Child Neurol. 2005; 47 (8): 571-576.

Tahmassebi JF, Curzon ME. Prevalence of drooling in

children with cerebral palsy attending special schools.

Dev Med Child Neurol. 2003; 45 (9): 613-617.

Crysdale WS, McCann C, Roske L, Joseph M, Semenuk

D, Chait P. Saliva control issues in the neurologically

challenged. A 30 year experience in team management.

Int J Pediatr Otorhinolaryngol. 2006; 70 (3): 519-527.

Brei TJ. Management of drooling. Semin in Pediatr

Neurol. 2003; 10 (4): 265-270.

Erbguth FJ. Botulinum Toxin, a historical note. Lancet.

; 351: 1820.

Lal D, Hotaling AJ. Drooling. Curr Opin Otolaryngol Head

Neck Surg. 2006; 14 (6): 381-386.

Brin MF. Botulinum toxin: chemistry, pharmacology,

toxicity and inmunology. Muscle Nerve Suppl. 1997; 6:

-168.

Brin MF. Basic and clinical aspects of BOTOX. Toxicon.

; 54 (5): 676-682.

Jongerius PH, Van Den Hoogen FJ, Van Limbeek J,

Gabreëls FJ, van Hulst K, Rotteveel JJ. Effect of bo-

tulinum toxin in the treatment of drooling: a controlled

clinical trial. Pediatrics. 2004; 114 (3): 620-627.

Crysdale WS, McCann C, Roske L, Joseph M, Semenuk

D, Chait P. Saliva control issues in the neurologically

challenged: a 30 year experience in team management.

Int J Pediatr Otorhinolaryngol. 2006; 70: 520-527.

Tan EK. Botulinum toxin treatment of sialorrhea: com-

paring different therapeutic preparations. Eur J Neurol.

; 13 (Suppl1): 60-64.

Reid SM, Johnstone MB, Westbury C, Rawicki B,

Reddihough DS. Randomized trial of botulinum toxin

injections into the salivary glands to reduce drooling

in children with neurological disorders. Dev Med Child

Neurol. 2008; 50: 123-128.

Thomas-Stonell N, Greenberg J. Three treatment ap-

proaches and clinical factors in the reduction of drooling.

Dysphagia. 1988; 3 (2): 73-78.

WeeFIM System. Clinical Guide, Version 5.01. Univer-

sity at Buffalo, Buffalo NY; 2000.

Suskind DL, Tilton A. Clinical study of botulinum –a toxin

in the treatment of sialorrhea in children with cerebral

palsy. Laryngoscope. 2002; 112 (1): 73-81.

Carod Artal FJ. Tratamiento de la sialorrea en enfer-

medades neurológicas mediante inyecciones trans-

cutáneas de toxina botulínica tipo A en las glándulas

parótidas. Neurología. 2003; 18 (5): 280-284.

López VLJ, Morales AF. Nuevas aplicaciones de la

toxina botulínica. Neurología. 1998; 13 (8): 388-394.

Lorenc ZP, Kenkel JM, Fagien S, Hirmand H, Nestor

MS, Sclafani AP et al. A review of onabotulinumtoxina

(Botox). Aesthet Surg J. 2013; 33 (1 Suppl): 9S-12S.

Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC.

Botulinum toxin type A on oral health in treating sia-

lorrhea in children with cerebral palsy: a randomized,

double-blind, placebo-controlled study. J Child Neurol.

; 26 (7): 838-843.

Scheffer AR, Erasmus C, van Hulst K, van Limbeek J,

Jongerius PH, van den Hoogen FJ. Effi cacy and duration

of botulinum toxin treatment for drooling in 131 children.

Arch Otolaryngol Head Neck Surg. 2010; 136 (9): 873-

Alrefai AH, Aburahma SK, Khader YS. Treatment of

sialorrhea in children with cerebral palsy: a double–blind

placebo controlled trial. Clin Neurol Neurosurg. 2009;

(1): 79-82.

Banerjee KJ, Glasson C, O’Flaherty SJ. Parotid and sub-

mandibular botulinum toxin A injections for sialorrhoea

in children with cerebral palsy. Dev Med Child Neurol.

; 48 (11): 883-887.

Walshe M, Smith M, Pennington L. Interventions for

drooling in children with cerebral palsy. Cochrane Da-

tabase Syst Rev. 2012; 11: CD008624.

Fuster-Torres MA, Berini-Aytés L, Gay-Escoda C.

Salivary gland application of botulinum toxin for the

treatment of sialorrhea. Med Oral Patol Oral Cir Bucal.

; 12 (7): E511-517.

Savarese R, Diamond M, Elovic E, Millis SR. Intraparotid

injection of botulinum toxin A as a treatment to control

sialorrhea in children with cerebral palsy. Am J Phys

Med Rehabil. 2004; 83 (4): 304-311.

Baird MW, Vargus-Adams J. Outcome measures used

in studies of botulinum toxin in childhood cerebral palsy:

a systematic review. J Child Neurol. 2010; 25 (6): 721-

Yalcinkaya EY, Caglar NS, Tugcu B, Tonbaklar A. Re-

habilitation outcomes of children with cerebral palsy. J

Phys Ther Sci. 2014; 26 (2): 285-289.

Published

2026-04-08

How to Cite

1.
Ortega-Peña S, Franco-Cendejas R. Medical importance of Staphylococcus epidermidis biofilm in joint prosthesis infections. Invest. Discapacidad [Internet]. 2026 Apr. 8 [cited 2026 Apr. 8];3(3):106-13. Available from: https://dsm.inr.gob.mx/indiscap/index.php/INDISCAP/article/view/905

Issue

Section

Evidence synthesis and meta-research

Most read articles by the same author(s)

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.